hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
== Morphology == This bacterium has a cell diameter is of 0.8–1.0 micrometers but does not have a definite length because of its multicellular filamentous structure. The bacterium is red to reddish-brown forms distinct red bacterial mats in the natural environment. R. castenholzii lacks internal vesicles, internal membranes, and complex structures. This species has gliding motility.
== History == Humans have inhabited the atoll since about 1,000 B.C. The islands were first settled by Austronesian islanders. The first European colonizers to Enewetak, Spanish explorer Álvaro de Saavedra Cerón, arrived on 10 October 1529. He called the island "Los Jardines" (The Gardens). In 1794, sailors aboard the British merchant sloop Walpole called the islands "Brown's Range" (thus, the Japanese name "Brown Atoll"). It was visited by about a dozen ships before the establishment of the German colony of the Marshall Islands in 1885.
Rusfertide, sold under the brand name Mimrylo, is a medication used for the treatment of polycythemia vera. It is a hepcidin mimetic. It was developed by Protagonist Therapeutics in partnership with Takeda Pharmaceuticals. It is given by subcutaneous injection. The most common adverse reactions include injection site reactions and anemia. Rusfertide was approved for medical use in the United States in August 2026. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body.
In 1738, Swiss physicist and mathematician Daniel Bernoulli postulated that the pressure of gases and heat were both caused by the underlying motion of molecules. Using his model he could predict the ideal gas law at constant temperature and suggested that the temperature was proportional to the velocity of the particles. This success was not followed up, in part because the then new tools of calculus allowed more progress using continuous models for gases. James Clerk Maxwell, a vocal proponent of atomism, revived the kinetic theory in 1860 and 1867. His key insight was that the velocity of particles in a gas would vary around an average value, introducing the concept of a distribution function. In the late 1800s, Ludwig Boltzmann used atomic models to apply kinetic theory to thermodynamics especially the second law relating to entropy. Boltzmann defended the atomistic hypothesis against major detractors from the time like Ernst Mach or energeticists like Wilhelm Ostwald, who considered that energy was the elementary quantity of reality. However an atomic model was not essential for the development of theory of thermodynamics. This became clear when Josiah Willard Gibbs introduced statistical mechanics in his 1902 book Elementary Principles in Statistical Mechanics. His logical and formal development of a new approach specifically avoided requiring an atomic hypothesis. Albert Einstein independently developed an approach similar to Gibbs, but with a completely different aim: Einstein set out to find a way to verify the atomic hypothesis through the kinetic theory.
The role of gastric acid in digestion was established in the 1820s and 1830s by William Beaumont on Alexis St. Martin, who, as a result of an accident, had a fistula (hole) in his stomach, which allowed Beaumont to observe the process of digestion and to extract gastric acid, verifying that acid played a crucial role in digestion.
Sources: en.wikipedia.org
== Financial history == Millipore Corporation had been publicly traded on the OTC, or NASDAQ, exchange where it had paid a cash dividend to shareholders every year since 1966. In 1987 Millipore Corporation moved from the NASDAQ exchange to the New York Stock Exchange, where it traded under the ticker symbol MIL. Millipore Corporation was on the S&P 500 list of the largest publicly traded companies in the United States until it was acquired by Merck kGaA in 2010. The deal was valued at approximately EUR 5.3 billion (US$7.2 billion). Merck KGaA is not associated with Merck & Co., although the two companies stem from the same parent company.
=== Biological effects and uses === Studies on mice have helped researchers understand the critical role of ANP in preventing hypertension or high blood pressure. When ANP-deficient mice were studied, they showed signs of hypertension when consuming too much salt. Similarly, when NPR-A, a receptor for ANP, was knocked out in mice, they also displayed hypertension and a reduced response to diuretics. This suggests that ANP is essential in regulating blood pressure and fluid balance. Interestingly, when NPR-A was knocked out specifically in the endothelial cells lining blood vessels, mice showed increased plasma volume, suggesting that ANP may regulate fluid balance by increasing the permeability of blood vessels in these cells. These findings indicate that ANP and its receptor NPR-A are essential in regulating mice's blood pressure and fluid balance. Recent advances in the biology of natriuretic peptides (NPs) have led to the developing of "designer" NPs. These peptides have larger surface areas compared to smaller natural molecules, making them better suited for activating specific receptors with minimal off-target effects. While inhibiting enzymatic degradation of peptides can boost endogenous peptides, it may not be enough to achieve optimal receptor stimulation. Therefore, designer peptides with specific properties could be a new strategy to improve upon existing therapies.
Tropaeolum tuberosum (mashua, see below for other names) is a species of flowering plant in the family Tropaeolaceae, grown in the Andes, particularly in Peru and Bolivia, and to a lesser extent in Ecuador as well as in some areas of Colombia, for its edible tubers, which are eaten cooked or roasted as a vegetable. It is a minor food source, especially for native Amerindian populations. Mashua is a herbaceous perennial climber growing to 2–4 m (7–13 ft) in height. It is related to garden nasturtiums, and is occasionally cultivated as an ornamental for its brightly coloured tubular flowers. The leaves are peltate, roundly five-lobed with a petiole that twines weakly but is not truly a tendril. The root is tuberous.
== Variations == Grilled: The noodles and sauce are put in a grilling basket. Fry: Popular primarily in Mishan. The noodles are fried and then brushed with sauce. Teppanyaki: This is the most common way to cook the dish using Teppanyaki cold noodles with onion, eggs and sausage.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.